ChangLin Lin

Mr. ChangLin Lin

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CLChun-Yu Lin
Chun-Yu Lin
YLYi-Chun Liu
Yi-Chun Liu
CCChou-Chen Chen
Chou-Chen Chen
MCMing-Cheng Chen
Ming-Cheng Chen
TCTeng-Yi Chiu
Teng-Yi Chiu
FCFENG FAN CHIANG
FENG FAN CHIANG
Background and Objective: Colorectal cancer (CRC) is the third most common cancer worldwide, with colon cancer accounting for approximately 60% of all CRC cases. Surgery remains the primary and most effective treatment. Robotic-assisted surgery (RAS) has emerged as a promising approach for colon cancer resection. This retrospective study compares RAS and laparoscopic-assisted surgery (LSS) for stage I–III colon cancer resections at a single medical center in East Asia. Methods: Between 1 January 2018, and 29 February 2024, patients undergoing colectomy were classified into right-side and left-side colectomies. Propensity score matching was conducted based on age group, gender, ASA score, and BMI to ensure comparability between groups. After matching, there were 50 RAS and 200 LSS cases for right colectomy (RC), and 129 RAS and 258 LSS cases for left colectomy (LC). Perioperative outcomes were compared between the two surgical approaches. The primary outcomes were recovery milestones, while secondary outcomes included complications and postoperative pain scores. Results: RAS demonstrated faster recovery milestones compared to LSS (hospital stay: 6.5 vs. 10.2 days, p = 0.005 for RC; 5.5 vs. 8.2 days, p < 0.001 for LC). RAS also resulted in lower rates of ileus (14% vs. 26%, p = 0.064 for RC; 6.2% vs. 15.9%, p = 0.007 for LC) and higher lymph node yields (31.4 vs. 26.8, p = 0.028 for RC; 25.8 vs. 23.9, p = 0.066 for LC). Major complication rates showed no significant difference between RAS and LSS (4.0% vs. 7.0%, p = 0.746 for RC; 4.7% vs. 3.1%, p = 0.563 for LC). Patients in the RAS group experienced earlier diuretic phases and reported significantly lower postoperative pain scores (3.0 vs. 4.1, p = 0.011 for RC; 2.9 vs. 4.1, p < 0.001 for LC). Conclusions: Robotic-assisted surgery is associated with faster recovery, lower rates of ileus (LC), higher lymph node yield (RC) and reduced postoperative pain compared to laparoscopic-assisted surgery for colon cancer resection.

12 December 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
BLBO-ZHI LIN
BO-ZHI LIN
CLChangLin Lin
ChangLin Lin
FCFENG FAN CHIANG
FENG FAN CHIANG
CCChou-Chen Chen
Chou-Chen Chen
MCMing-Cheng Chen
Ming-Cheng Chen
SHShang-Chih Huang
Shang-Chih Huang
Aim: The tumor staging of colorectal cancer (CRC) plays a significant role in both treatment and prognosis, impacting surgical planning and adjuvant therapy decisions. Currently, the staging of CRC is based on the TNM system developed by the American Joint Committee on Cancer. Prior studies have suggested that survival rates and recurrent rates of T4a tumors appear to be worse than that of T4b tumors, although there is currently no consensus. Therefore, we collected patient data from Taichung Veterans General Hospital over the past decade in order to conduct further research. Method: Between 2010 and 2018, a total of 5760 newly diagnosed CRC patients were seen at the hospital. To eliminate the influence of any local lymph node involvement or distant organ metastasis on the research results, we focused on patients with pathologic Stage IIc disease (T4a-bN0M0). Patients with rectal cancer who had received neoadjuvant concurrent chemoradiotherapy were excluded. Ultimately, 132 patients were included in this study. A multivariate Cox regression analysis was conducted to identify independent risk factors for both 10-year cancer-specific survival (CSS) and overall survival (OS). Results: A total of 132 patients were included in the study, with 90 classified as T4a and 42 as T4b. The 10-year CSS for pT4a and pT4b was 72.5% and 56.5%, respectively, with a p-value of 0.011. The 10-year OS for pT4a and pT4b was 48.4% and 42.5%, respectively, with a p-value of 0.086. There was no significant difference in the site of first recurrence between the pT4a and pT4b groups (p-value = 0.936). Overall, patients who received adjuvant chemotherapy therapy had a significantly better prognosis (p-value < 0.05). However, there was no significant difference in prognosis between oral 5-FU and FOLFOX. Conclusion: Based on our data, patients diagnosed with pathologic T4aN0M0 CRC appeared to experience a trend toward better 10-year OS when compared to those with T4bN0M0 disease, but this trend lacks statistical significance. Patients with locally advanced Stage II colon cancer clearly benefited from adjuvant chemotherapy therapy; therefore, FOLFOX may not necessarily be required.

4 November 2025 in Journal of Surgical Research
Verified
Journal Article
Closed access
CLChangLin Lin
ChangLin Lin
FCFeng-Fan Chiang
Feng-Fan Chiang
MCMing-Cheng Chen
Ming-Cheng Chen
CLChun-Yu Lin
Chun-Yu Lin
SHShang-Chih Huang
Shang-Chih Huang
CLChing Shiang Lin
Ching Shiang Lin

28 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YTYu Kang Tseng
Yu Kang Tseng
CLChangLin Lin
ChangLin Lin
SCShih-Wei Chiang
Shih-Wei Chiang
FCFENG FAN CHIANG
FENG FAN CHIANG
Background: Taiwan’s transition to a super-aged society presents challenges in managing elderly patients with refractory metastatic colorectal cancer (mCRC). This study evaluated the real-world effectiveness of trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus regorafenib in this specific geriatric population. Methods: A retrospective study analyzed patients aged ≥ 65 treated between 2019 and 2023. Patients received regorafenib (n = 46) or FTD/TPI plus bevacizumab (n = 35). Primary endpoints included overall survival (OS) and time to treatment failure (TTF). Results: FTD/TPI plus bevacizumab was associated with significantly longer median OS compared to regorafenib (12.5 vs. 6.5 months; p = 0.039). In multivariate analysis, the combination regimen was identified as an independent predictor of favorable TTF (adjusted HR 0.44, 95% CI 0.22–0.91, p = 0.028). Regorafenib was associated with symptomatic toxicities like hand–foot skin reaction (58.7%), while the combination primarily caused asymptomatic neutropenia. Crucially, permanent discontinuation due to adverse events was significantly lower in the combination arm (2.9% vs. 30.4%, p < 0.001), facilitating a higher proportion of patients receiving subsequent systemic therapy (45.7% vs. 17.4%, p = 0.011). Conclusions: FTD/TPI plus bevacizumab is associated with improved survival outcomes and better tolerability than regorafenib. By demonstrating a manageable safety profile and minimizing treatment attrition, this regimen ensures a sustainable continuum of care, representing a favorable therapeutic option for elderly patients.

6 January 2026 in Food & Function
Verified
Journal Article
Closed access
PDF file
HCHsuan-Yin Chen
Hsuan-Yin Chen
CLChangLin Lin
ChangLin Lin
CCChou-Chen Chen
Chou-Chen Chen
JLJin-Yuarn Lin
Jin-Yuarn Lin
Possible immunomodulatory effects of caffeic acid on BALB/c nude mice subcutaneously loaded with HT-29 cells.

6 May 2025 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
CLChangLin Lin
ChangLin Lin
SCShih-Wei Chiang
Shih-Wei Chiang
SHShih-Feng F. Huang
Shih-Feng F. Huang
CHChun-Yen Hung
Chun-Yen Hung
FCFENG FAN CHIANG
FENG FAN CHIANG
An abstract is unavailable. This article is available as a PDF only.